
RayzeBio Investor Relations Material
Latest events

Q3 2023
13 Nov, 2023

Corporate Presentation
12 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from RayzeBio Inc
Access all reports
RayzeBio Inc is a biotechnology firm concentrated on developing radiopharmaceutical therapeutics (RPT) for cancer treatment. Their leading drug candidate, RYZ101, is in clinical trials aimed at treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Additionally, RayzeBio is working on RYZ801, a novel proprietary peptide targeting GPC3 for the treatment of hepatocellular carcinoma (HCC), among other innovative drug candidates targeting various cancers. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
RYZB
Country
🇺🇸 United States